Based: San Diego, CA
Investors: Undisclosed Corporate Investor
Scoop: Sangart is currently conducting Phase III trials of its lead product candidate, Hemospan, a hemoglobin-based oxygen carrier designed to serve as an alternative to blood transfusions. The trials are designed to gauge the ability of Hemospan to prevent and treat hemodynamic instability, especially hypotension, or low blood pressure, during orthopedic surgery and will include more than 800 patients.
Sangart garners $50M in VC. Report